Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 12/20 | 0.73 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.65 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CRHBP | P24387 | 1/20 | 0.37 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3150562 | 0.99 | SLC6A2 (0.73) | SLC6A2SLC6A4OPRL1OPRM1OPRK1 | |
| SCHEMBL3138374 | 0.95 | SLC6A2 (0.72) | SLC6A2SLC6A4OPRL1OPRM1OPRK1 | |
| SCHEMBL4634820 | 0.95 | SLC6A2 (0.72) | SLC6A2SLC6A4OPRL1OPRM1OPRK1 | |
| SCHEMBL3151314 | 0.95 | SLC6A2 (0.72) | SLC6A2SLC6A4OPRL1OPRM1OPRK1 | |
| SCHEMBL3142477 | 0.84 | SLC6A2 (1.00) | SLC6A2SLC6A4OPRL1 | |
| SCHEMBL3142462 | 0.84 | SLC6A2 (1.00) | SLC6A2SLC6A4OPRL1 | |
| SCHEMBL3131929 | 0.83 | SLC6A2 (1.00) | SLC6A2SLC6A4 | |
| SCHEMBL3137325 | 0.83 | SLC6A2 (1.00) | SLC6A2SLC6A4 | |
| SCHEMBL3150624 | 0.82 | SLC6A2 (0.53) | SLC6A2SLC6A4OPRL1OPRM1OPRK1 | |
| SCHEMBL3141385 | 0.79 | SLC6A2 (1.00) | SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687529-B2 | Substituted propylamine derivatives and methods of their use | WYETH LLC (US) | 2010-03-30 | — | — | US | disclosed |
| US-20070072928-A1 | treatment of conditions ameliorated by monoamine reuptake including vasomotor symptoms, sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders; 1'-[3-(methylamino)-1-phenylpropyl]spiro[cyclohexane-1,3'-indol]-2'(1'H)-one | WYETH (US) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072928-A1 | treatment of conditions ameliorated by monoamine reuptake including vasomotor symptoms, sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders; 1'-[3-(methylamino)-1-phenylpropyl]spiro[cyclohexane-1,3'-indol]-2'(1'H)-one | TPH1, HTR1A, HTR5A | SLC6A2 9/4885SLC6A4 4/4885OPRL1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.